Loading company…
New York biotechnology company developing non-viral gene therapies, led by XT-150, for chronic inflammatory conditions.
Founded in 2009 and headquartered in New York, US, Xalud Therapeutics develops non-viral plasmid DNA gene therapies for chronic inflammatory conditions, mainly musculoskeletal and neurodegenerative indications. Its lead candidate, XT-150, is a locally injectable therapy that expresses a modified interleukin-10. The company raised USD 18.17 mn in a Series C round on May 18, 2021, led by PBM Capital Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in